Due to lack of central venous access, a direct right atrial catheter
was inserted at surgery for monitoring and to give parenteral nutrition of intralipid and glucose-amino acid solution.
The study demonstrated that the addition of right atrial catheter
ablation to a regimen of previously ineffective antiarrhythmic drugs (AADs) yields a significant reduction in the frequency, duration and severity of AF episodes and symptoms.
Nasdaq SC: CRDM), today announced data from the REVELATION Tx(R) Phase III trial was published in an article entitled "Hybrid Therapy with Right Atrial Catheter
Ablation and Previously Ineffective Antiarrhythmic Drugs for the Management of Atrial Fibrillation" in the April 29, 2005 issue of the Journal of Interventional Cardiac Electrophysiology, Vol.